Fibrobiologics Inc
FBLG0.252USD
-0.000-0.08%
Cierre 02/09, 16:00（ET）Cotizaciones retrasadas 15 min
8.17MCap. mercado
PérdidaP/E TTM
Más Datos de Fibrobiologics Inc Compañía
FibroBiologics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing and commercializing fibroblast-based therapies for patients suffering from chronic diseases with significant unmet medical needs, including wound healing, multiple sclerosis, degenerative disc disease, psoriasis and certain cancers, and potential human longevity applications including thymic involution reversal. Its product candidates include CybroCell, CYMS101 and CYWC628. CybroCell is an allogeneic fibroblast cell-based therapy for degenerative disc disease. This technology is being designed as an alternative method for repairing the cartilage of the intervertebral disc (or any other articular cartilage). It is developing CYMS101 as an allogeneic fibroblast cell-based therapy to treat multiple sclerosis (MS) and has completed the Phase I study. It is developing CYWC628 as an allogeneic fibroblast cell-based therapy for wound healing. Its CYPS317 is used for the treatment of Psoriasis.
Información de Fibrobiologics Inc
Símbolo de cotizaciónFBLG
Nombre de la empresaFibrobiologics Inc
Fecha de salida a bolsaJan 31, 2024
Director ejecutivoO'Heeron (Pete)
Número de empleados13
Tipo de seguridadOrdinary Share
Fin del año fiscalJan 31
Dirección455 E. Medical Center Blvd
CiudadHOUSTON
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal77598
Teléfono12816715150
Sitio Webhttps://fibrobiologics.com/
Símbolo de cotizaciónFBLG
Fecha de salida a bolsaJan 31, 2024
Director ejecutivoO'Heeron (Pete)
Ejecutivos de Fibrobiologics Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Ruben Garcia
Mr. Ruben Garcia
General Counsel
General Counsel
140.00K
+140000.00%
Dr. Hamid Khoja, Ph.D.
Dr. Hamid Khoja, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
31.25K
--
Mr. Robert E. Hoffman, CPA
Mr. Robert E. Hoffman, CPA
Director
Director
7.50K
--
Dr. Victoria Niklas, M.D.
Dr. Victoria Niklas, M.D.
Independent Director
Independent Director
--
--
Mr. Richard Cilento, Jr.
Mr. Richard Cilento, Jr.
Independent Director
Independent Director
--
--
Ms. Stacy Coen
Ms. Stacy Coen
Independent Director
Independent Director
--
--
Mr. Matthew Link
Mr. Matthew Link
Independent Director
Independent Director
--
--
Mr. Pete O'Heeron
Mr. Pete O'Heeron
Chairman of the Board, Chief Executive Officer, Founder
Chairman of the Board, Chief Executive Officer, Founder
--
--
Mr. Nic Johnson
Mr. Nic Johnson
IR Contact Officer
IR Contact Officer
--
--
Mr. Jason D. Davis
Mr. Jason D. Davis
Chief Financial Officer
Chief Financial Officer
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Ruben Garcia
Mr. Ruben Garcia
General Counsel
General Counsel
140.00K
+140000.00%
Dr. Hamid Khoja, Ph.D.
Dr. Hamid Khoja, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
31.25K
--
Mr. Robert E. Hoffman, CPA
Mr. Robert E. Hoffman, CPA
Director
Director
7.50K
--
Dr. Victoria Niklas, M.D.
Dr. Victoria Niklas, M.D.
Independent Director
Independent Director
--
--
Mr. Richard Cilento, Jr.
Mr. Richard Cilento, Jr.
Independent Director
Independent Director
--
--
Ms. Stacy Coen
Ms. Stacy Coen
Independent Director
Independent Director
--
--
Desglose de ingresos
La empresa aún no ha revelado los datos relevantes.
La empresa aún no ha revelado los datos relevantes.
Por negocio
Por región
La empresa aún no ha revelado los datos relevantes.
Estadísticas de accionistas
Actualizado: dom., 1 de feb
Actualizado: dom., 1 de feb
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
O'Heeron (Peter)
8.88%
Golden Knight Inc LP
8.53%
The Vanguard Group, Inc.
1.83%
Yorkville Advisors Global, LP.
0.77%
Millennium Management LLC
0.67%
Otro
79.32%
Accionistas
Accionistas
Proporción
O'Heeron (Peter)
8.88%
Golden Knight Inc LP
8.53%
The Vanguard Group, Inc.
1.83%
Yorkville Advisors Global, LP.
0.77%
Millennium Management LLC
0.67%
Otro
79.32%
Tipos de accionistas
Accionistas
Proporción
Individual Investor
9.32%
Corporation
8.53%
Investment Advisor
4.75%
Hedge Fund
1.71%
Investment Advisor/Hedge Fund
1.45%
Research Firm
0.25%
Bank and Trust
0.21%
Family Office
0.01%
Otro
73.76%
Participación institucional
Actualizado: lun., 8 de dic
Actualizado: lun., 8 de dic
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q4
135
5.57M
8.37%
-1.10M
2025Q3
125
5.16M
16.27%
+26.14K
2025Q2
124
5.13M
16.68%
-1.32M
2025Q1
115
6.45M
16.82%
+104.96K
2024Q4
107
5.96M
16.68%
+467.89K
2024Q3
99
5.49M
10.74%
+2.00M
2024Q2
74
3.47M
1.58%
+2.95M
2024Q1
20
483.30K
0.00%
+483.30K
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
O'Heeron (Peter)
5.91M
8.88%
--
--
Dec 26, 2025
Golden Knight Inc LP
5.67M
8.53%
+3.54M
+165.82%
Dec 26, 2025
The Vanguard Group, Inc.
1.23M
1.85%
--
--
Sep 30, 2025
Yorkville Advisors Global, LP.
509.79K
0.77%
-334.32K
-39.61%
Sep 30, 2025
Millennium Management LLC
446.21K
0.67%
-34.44K
-7.16%
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
434.68K
0.65%
-280.89K
-39.25%
Sep 30, 2025
Landscape Capital Management, L.L.C.
350.00K
0.53%
+350.00K
--
Sep 30, 2025
Cascade Financial Partners, LLC
298.08K
0.45%
+7.50K
+2.58%
Sep 30, 2025
GTS Securities LLC
308.66K
0.46%
+308.66K
--
Sep 30, 2025
Geode Capital Management, L.L.C.
288.95K
0.43%
--
--
Sep 30, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 6 de dic
Actualizado: sáb., 6 de dic
Nombre
Proporción
iShares Russell 2000 Growth ETF
0%
ProShares Hedge Replication ETF
0%
Global X Russell 2000 ETF
0%
ProShares UltraPro Russell2000
0%
Proshares Ultra Russell 2000
0%
Texas Capital Texas Small Cap Equity Index ETF
0%
iShares Russell 2000 ETF
0%
iShares Micro-Cap ETF
0%
iShares Russell 2000 Growth ETF
Proporción0%
ProShares Hedge Replication ETF
Proporción0%
Global X Russell 2000 ETF
Proporción0%
ProShares UltraPro Russell2000
Proporción0%
Proshares Ultra Russell 2000
Proporción0%
Texas Capital Texas Small Cap Equity Index ETF
Proporción0%
iShares Russell 2000 ETF
Proporción0%
iShares Micro-Cap ETF
Proporción0%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Fecha ex-dividendo
Tipo
Relación
Sin datos
Fecha
Fecha ex-dividendo
Tipo
Relación
Sin datos
